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 Abstract: 31 
Purpose: 32 
Use of antibiotics can give rise to the selection of resistant bacteria.  It remains unclear whether antibiotic 33 
use in primary care can influence bacterial resistance incidence in patients when hospitalized.  The aim 34 
of this study is to explore the impact of prior community antibiotic usage on hospital detected multidrug-35 
resistant gram-negative (MRGN) incidence rate. 36 
Methods: 37 
This pharmacoepidemiological study was case-control in design, and was carried out in the Antrim Area 38 
Hospital (N. Ireland) in two phases. In phase 1, the controls were matched according to: age, gender, 39 
admission ward, date of admission and age-adjusted Charlson co-morbidity index score.  During the 40 
second phase, controls were selected randomly from the total population of admissions to the hospital 41 
over the 2-year study period.  42 
Results:  43 
In phase 1, multivariate analysis revealed that prior exposure to second and third generation 44 
cephalosporins (p=0.004) and fluoroquinolones (p=0.023) in primary care was associated with an 45 
increased likelihood of MRGN detection in inpatients. In phase 2, an independent relationship between 46 
an increased risk of identification of MRGN while hospitalised was associated with: prolonged 47 
hospitalisation (p<0.001), being elderly (p<0.001), being female (p=0.007) and having genitourinary 48 
disease (p<0.001).   49 
Conclusion: 50 
This study provides clear evidence which supports the need to optimise antibiotic use in primary care to 51 
help reduce MGRN incidence in hospitalised patients.  52 
 Keywords: Primary care, Antibiotic prescribing, Multidrug-resistant Gram-negative bacteria (MRGN), 53 
Hospitalised Patients, Antibiotic resistance, Pharmacoepidemiology 54 
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 Introduction 71 
Klebsiella pneumoniae and Escherichia coli represent the two main extended-spectrum β-lactamase 72 
(ESBL)-producing bacteria; they are listed as multidrug-resistant gram-negative (MRGN) bacteria for 73 
which new treatment regimens are urgently required [1].  Extended spectrum β-lactamases are a group 74 
of β-lactamase enzymes which hydrolyse and inactivate several types of β-lactam antibiotics [including 75 
expanded-spectrum (second and third generation) cephalosporins and monobactams] [1-4].  High 76 
antibiotic consumption is a well-established risk factor associated with the acquisition of Clostridium 77 
difficile infection (CDI), meticillin-resistant Staphylococcus aureus (MRSA) and MRGN bacteria [5, 78 
6].  Many studies have demonstrated that infection with MRGN bacteria is associated with an increased 79 
rate of morbidity and mortality together with other measures of clinical failure including: longer 80 
hospital stay and/or increased antibiotic consumption within the hospital and community settings [2-6, 81 
7-11].  Since the late 1990s, multidrug-resistant CTX-M-producing Escherichia coli have been 82 
detected within the primary healthcare setting as a leading cause of urinary tract infections and 83 
community-onset bacteraemia [7, 12-14].  Few investigations have been performed to determine the 84 
impact of fluoroquinolone use within the community setting on the resistance level in fluoroquinolone-85 
resistant Escherichia coli.  Cooper et al. (2004) stated that the separation of primary and secondary 86 
healthcare settings, when linking antibiotic resistance to antibiotic use, is artificial, as the antibiotic 87 
resistance reservoir can be spread to hospitals from the surrounding primary care community and vice 88 
versa [15].   It has been proposed by Gallini et al. (2010) that studies with ecological (population) 89 
designs have significant value in evaluating the link between, fluoroquinolone use and FQ-R 90 
Escherichia coli, as such studies consider the ecological nature of the problem of antibiotic resistance 91 
[16].  Nevertheless, these authors suggested that such studies may have some limitations, indicating the 92 
need for conducting studies at both the population level and the individual patient level.  In an earlier 93 
paper, Lopez-Lozano et al. (2000) emphasised that ecologic-level studies could be used to propose 94 
future interventions, but that individual patient level designs allow patient factors (e.g. patient 95 
demographics) to be taken into account [17].  Overall, there is a general view within the literature that 96 
there is the need for conducting studies at both the population level and the individual patient level to 97 
better understand the relationship between antibiotic use and resistance development.  The influence of 98 
primary care antibiotic prescription on MRGN incidence rates in hospitalised patients (within the 99 
hospital which is the focus of the present study, i.e. the Antrim Area Hospital), was investigated in a 100 
 recently published ecologic-level study [18].  The present work is a complementary study with the goal 101 
of evaluating the impact of community antibiotic prescribing at the individual patient level on MRGN 102 
bacteria detected in hospital. 103 
Aim of the study 104 
The aim of the investigation presented in this paper was to assess the impact of antibiotic prescribing, 105 
during the previous 3, 6 and 12 months, in the community served by a medium sized hospital in N. 106 
Ireland (Antrim Area Hospital; 426 beds) on the identification of MRGN bacteria in patients within the 107 
study site hospital. 108 
Method 109 
Setting and study period 110 
The study was carried out in the Antrim Area Hospital (AAH) and its surrounding geographical 111 
community.  Data required for the purposes of this study covered the period January 2012 to December 112 
2013. 113 
Case definitions 114 
A multidrug-resistant gram-negative bacteria case was identified as a patient in whom a 3MRGN strain 115 
of bacteria (i.e. resistant to three of the four groups listed below) was recovered and identified, during 116 
their in-patient stay within the AAH between January 2012 and December 2013.  Only 3MRGN 117 
isolates from any clinical samples were included.  These isolates included both infection and 118 
colonization with 3MRGN bacteria. The classification of detected 3MRGN bacteria is based on 119 
pathogen susceptibility to the most important antibiotic groups [acylureidopenicillins, 3rd and 4th 120 
generation cephalosporins, carabapenems and fluoroquinolones; 19].  121 
 122 
 123 
 Age-adjusted Charlson co-morbidity index score 124 
To estimate the Charlson co-morbidity index score in the present study, the ICD-10 coding system for 125 
diseases was employed [20].  An age-adjusted co-morbidity index score was calculated for all the 126 
patients involved in the research, by applying one additional point for each decade over 40 years of age 127 
to the original index score [20, 21]. 128 
Study design 129 
In order to identify particular antibiotics that were associated with hospital detected MRGN and to 130 
identify risk factors for identification of MRGN organisms from clinical samples, two separate phases 131 
of research were implemented involving matching cases to two separate control groups.  132 
Phase 1: Comparisons were made between case patients (i.e. identified as MRGN-positive patients) 133 
and a matched control group (two control patients for each case patient).  The control group in this 134 
phase included patients with no positive result for MRGN, matched to case patients according to age 135 
(two categories: 16-65 years and >65), gender, admission ward, date of admission (±30 days) and age-136 
adjusted Charlson co-morbidity index score (two categories: 0-2 and >2).   137 
 Phase 2: In order to determine other risk factors for hospital detected MRGN pathogens (in particular 138 
those used as matching criteria in phase 1) the cases were compared with a second control group (two 139 
control patients for each case patient). The second control group included patients chosen randomly 140 
[i.e. randomisation was achieved using computer software to generate random numbers] [22] from the 141 
pool of patients who had no positive result for MRGN and who were admitted to the AAH over the two 142 
year study period.  143 
 144 
 145 
 146 
 147 
 148 
 Study inclusion criteria  149 
Patients> 16 years admitted to Antrim hospital over the period Jan 2012-Dec 2013 and was specified as 150 
one of the following:  151 
 Positive-MRGN patient  152 
 Matched control patient 153 
 Randomly selected control patient 154 
Study exclusion criteria 155 
The following patients were excluded: 156 
 paediatric patients (i.e. patients under the age of 16 years)  157 
 patients with scheduled admissions 158 
Data linkage 159 
Data for the case participants and the two sets of control patients were linked to the Health and Social 160 
Care Business Services Organisation (BSO; Northern Ireland) primary care prescription records of 161 
antibiotic use within primary care over the previous 12 months.   162 
Microbiology data 163 
Details on MRGN isolates were obtained from the Northern Health Trust clinical microbiology 164 
computerized record systems over the two year study period.  Hospital detected MRGN throughout this 165 
paper refer to isolates that were recovered during the patient’s hospital stay (hospital-onset and 166 
community-onset).  Only the first unique positive MRGN isolates for individual patients, throughout the 167 
study period, were recorded (i.e. duplicated positive results were excluded).  For the detection of MRGN, 168 
the methodology of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) was 169 
routinely employed within the hospital [4, 18, 23].  Each patient was labelled as having community-onset 170 
MRGN when he/she had the organism(s) detected within the first 48 hours after hospital admission or 171 
with hospital-onset MRGN when this detection occurred 48 hours or more after hospital admission. 172 
 173 
 Statistical analyses 174 
The patients chosen for this study consisted of a convenience sample and included all cases over a two-175 
year study period.  The following statistical procedures were performed in phase 1: Data relating to 176 
previous antibiotic exposure and other risk factors were summarised using descriptive statistics.  177 
Previous antibiotic prescribing in the primary care setting was measured (i.e. presented as cumulative 178 
count of treatment courses) during the periods: 0-3 months, 0-6 months and 0-12 months prior to 179 
admission.  For the purposes of statistical analyses, in line with agents that have been found to be 180 
associated with identification of MRGN in previous international research, antibiotics were categorised 181 
into penicillin combinations, fluoroquinolones, second and third generation cephalosporins and 182 
macrolides.  To identify any association between previous antibiotic exposure and hospital detected 183 
MRGN incidence rates in the hospitalised patients, univariate analyses were conducted as follows: (i) 184 
to evaluate associations between the continuous variables, either the Student paired t-test or the 185 
Wilcoxon test was carried out, based on the normality of data distribution; and (ii) the McNemar's test 186 
was used with categorical variables.  Following this, a backward multivariate logistic regression was 187 
carried out [with the outcome: MRGN (yes/no)] using the following models, to identify significant 188 
variables:  Model (1a) included the antibiotic groups of interest prescribed in primary care over the 3 189 
months prior to admission together with all non-antibiotic risk factors which  exhibited a  P value of 190 
0.25 or lower on univariate analyses;  Model (1b) covered the same ground for antibiotics prescribed in 191 
primary care in the 6 months prior to admission; and Model (1c) as for the previous models but 192 
covering the period of the 12 months prior to admission.  To measure the influence of each explanatory 193 
variable (e.g. previous antibiotic use or other risk factors) on the dependent variable (hospital detected 194 
MRGN), odds ratios were utilised.  All variables which resulted in a significance level of P ≤0.05 in the 195 
multivariate models were deemed statistically significant.  In phase 2, a similar statistical approach to 196 
that outlined above was repeated using the second control group, the only difference being that for 197 
univariate analysis, to evaluate associations between the continuous variables, either the Student t-test 198 
or the Mann-Whitney U-test was carried out, based on the normality of data distribution while the 199 
Pearson Chi Square was used with categorical variables.  Similar statistical approaches to that 200 
mentioned above (in phase 1 and phase 2) were repeated to examine the impact of antibiotic 201 
prescribing in primary care on isolation of hospital-onset MRGN and community-onset MRGN within 202 
 the patient cohort. All statistical analyses were carried out using the Statistical Package for Social 203 
Sciences (Windows Version 20.0; SPSS®, Chicago). 204 
Results 205 
Study population  206 
In total, 183 MRGN isolates were recovered from hospitalised patients within the AAH, between January 207 
2012 and December 2013.  The overall prevalence rate of MRGN was 0.088 cases/100 bed-days (0.74%).  208 
After applying the study inclusion criteria, 98 unique patients harbouring MRGN were eligible, and 209 
comprised the study cases group (Table 1).  Of these 98 patients, 54 (55.1%) were identified as having a 210 
community-onset detection; while 44 (44.9%) were defined as having a hospital-onset detection.  Of 211 
interest, the mean time from admission to detection of MRGN bacteria was 6 days (Table 1).   212 
Microbiological characteristics of MRGN strains 213 
E. coli was found to be the most frequently (75.3%) detected pathogen among the MRGN organisms, 214 
followed by, in descending order, Klebsiella pneumoniae (8.2%), Coliforms (8.2%), Proteus mirabilis 215 
(3.1%), Morganella morganii (2.1%), Klebsiella oxytoca (1.0%), Enterobacter aerogens (1.0%) and 216 
Enterobacter cloacae (1.0%; Table1). 217 
Antibiotic prescribing in primary care  218 
The most commonly prescribed antibiotics, i.e. average number of treatment courses (the count of 219 
antibiotic items prescribed to a given patient) in primary care for the case and matched control patients 220 
(Phase 1; Figure 1) during the 0-12 month period was found to be cephalosporin antibiotics (cases: 221 
1.82; matched controls: 0.45).  Data for Phase 2 (Figure 1) shows that cephalosporin antibiotics were 222 
again the most frequently prescribed antibiotics, during the 0-12 month period in primary care.  The 223 
case patients received a mean of 1.82 treatment courses, while a mean of 0.46 treatment courses was 224 
dispensed to the randomly selected control patients.   225 
 226 
 Fig. 1 Average number of antibiotic treatment courses (of second and third generation cephalosporins, 227 
fluoroquinolones, penicillin combinations and macrolides), which were prescribed for the cases, matched 228 
(phase 1) and randomly selected control patients (phase 2) in primary care, during the previous 3 month, 229 
6 month and 12 month periods. 230 
Clinical and general characteristics of study population 231 
Phase 1 cohort 232 
 In phase 1, 196 patients without an MRGN bacterial isolation were matched and compared with the 98 233 
MRGN cases.  The data in Table 2 shows that the matching of the selected parameters age, gender, 234 
admission ward and age-adjusted Charlson co-morbidity index was carried out effectively.  Further 235 
details on the demographics and baseline characteristics of the cases and control groups in phase 1 are 236 
also presented in Table 2. 237 
Phase 2 cohort 238 
In phases 2, a total of 200 patients (with no MRGN) were selected randomly, to comprise the second 239 
control group.  Out of the 98 case patients and 200 control patients, 64.3% and 53.0% were female, 240 
respectively.  The mean age was found to be higher (73.3 years) in case patients compared to control 241 
patients (61.1 years). The mean age-adjusted Charlson co-morbidity index score was higher (3.8), in 242 
case patients compared to control patients (2.9).  When mean hospitalisation period of case patients 243 
was compared with that in control patients, the difference was large (cases: 13.6 days; control: 5.0 244 
days).  Further demographic and baseline characteristics of the control groups in phase 2, are also 245 
presented in Table 2. 246 
Univariate analysis of variables associated with MRGN bacteria 247 
In phase 1 and 2, individual relationships were identified between MRGN detected in hospital and 248 
variables with P values ≤ 0.25, as displayed in Table 2. 249 
 250 
 251 
 Multivariate analysis of risk factors for MRGN detected in hospital  252 
Phase 1 (matched controls)-3 month model (model 1a) 253 
The multivariate analysis model for this category, identified that a prolonged hospitalisation period and 254 
having a primary diagnosis of a genitourinary system disease(s) were independent predictors for 255 
hospital detected MRGN.  The presence of genitourinary disease (genitourinary infectious diseases 256 
were excluded) in hospitalised patients was found to be associated with a 443.0% increase in the 257 
likelihood of identification of a hospital detected MRGN bacteria (coefficient 1.489; CI 95% 1.51-258 
13.00; P = 0.007; Table 3).  Additionally, for every one day increase in length of hospital stay, there 259 
was a 4.0% higher risk of isolation of MRGN while hospitalised (coefficient 0.040; CI 95% 1.02-1.06; 260 
P < 0.001).   261 
Phase 1 (matched controls)–6 month model (model 1b) 262 
The multivariate analysis of variables (included this model) determined that per each one day increase 263 
in period of stay in hospital, the odds of hospital MRGN detection was greater by 4.0% (coefficient 264 
0.041, CI 95% 1.02-1.07, P < 0.001; Table 3). 265 
Phase 1 (matched controls)–12 month model (model 1c) 266 
Multivariate analysis for model 1c, revealed that previous prescription of a fluoroquinolone or a 267 
cephalosporin (second and third generation) in primary care during the prior 12 month period was 268 
significantly and independently associated with the isolation of MRGN while hospitalised.  For each 269 
prescribed treatment course of a fluoroquinolone, the risk of identification of MRGN in hospital was 270 
found to be higher by 55.0% (coefficient 0.438; CI 95% 1.06-2.26; P = 0.023).  In relation to previous 271 
exposure to second and third generation cephalosporins, per each increase in the number of courses 272 
prescribed, the likelihood of isolation of hospital MRGN increased by 19.0% (coefficient 0.177; CI 273 
95% 1.06-1.35; P = 0.004; Table 3). 274 
 275 
 Phase 2 (randomly selected controls)-3 month, 6 month and 12 month models (model 2a, model 276 
2b and model 2c) 277 
This cohort resulted in the identification of additional variables (i.e. ‘non-antibiotic’ host-related 278 
factors) which could not be identified in phase 1 of the study due to the variables being used as 279 
matching criteria.  The results of multivariate analysis, using models 2a, 2b and 2c, were found to be 280 
exactly the same.  The following variables were indicated as potential independent predictors for 281 
hospital detected MRGN: having a higher age, longer hospitalisation period, being diagnosed primarily 282 
with genitourinary disease(s) and being female (226.0% greater in hospitalised female patients, 283 
compared with hospitalised male patients; coefficient 0.813; CI 95% 1.25–4.06; P = 0.007).  284 
Genitourinary underlying disease(s) as a primary diagnosis resulted in a 756.0% higher likelihood of 285 
producing MRGN isolates during the hospital stay (coefficient 2.022; CI 95% 2.54-22.45; P < 0.001).  286 
An increase in age (by one year over the age 16 years old) led to a 4.0% increase in risk of detection of 287 
MRGN bacteria in hospital (coefficient 0.037; CI 95% 1.02–1.06; P < 0.001).  For each one day rise in 288 
length of hospital stay, the odds of recovery of hospital MRGN rose by 6.0% (coefficient 0.053; CI 289 
95%; 1.03–1.09; P < 0.001; Table 3).   290 
Discussion 291 
In the United States in studies published in 2013 and 2014, approximately 3.9% of community-onset 292 
Escherichia coli infection strains have been determined to be producers of ESBLs [4, 24].  In the 293 
United Kingdom, the proportion of MRGN Escherichia coli strains increased from 0.8% in 2002 to 294 
11.2% in 2006; there was also an increase in prevalence rate of MRGN Klebsiella pneumoniae isolates 295 
in the UK over the same period (from 0.4% to 10.1%) [25].  A systematic review and meta analysis 296 
conducted in July 2015 showed that the prevalence of MRGN (pooled) was higher in Africa and Asia 297 
(ranging from 15% to 46%,) and lower in the Americas (2%) northern (4%), and southern (6%), and 298 
central (3%) Europe [26].   299 
Most of antibiotic prescriptions are written in outpatient settings to treat patients with acute respiratory 300 
conditions, such as pharyngitis, sinus infections, middle ear infections, viral upper respiratory 301 
infections (i.e., the “common cold”), bronchitis, bronchiolitis, asthma, allergies, influenza, and 302 
pneumonia.  Beyond respiratory conditions, a number of other conditions are commonly treated with 303 
 antibiotics in outpatient settings, including urinary tract infections (UTIs), skin infections, and acne 304 
[27]. 305 
In the present study, the majority of MRGN isolates were documented to be Escherichia coli bacteria 306 
and the most frequent specimen was urine.  It is well documented that there are reservoirs of resistant 307 
Escherichia coli isolates within community settings and that organisms can be ‘imported’ into hospitals 308 
when patients are admitted [26, 28].  309 
The majority of previous studies that assessed the determinants of MRGN bacteria have neglected vital 310 
issues that need to be addressed, including ‘dose-accumulation’, i.e. the time-dependent impact of prior 311 
treatment with antibiotics on the emergence of MRGN isolates in the primary and secondary care settings.  312 
In most prior studies antibiotic use has been included as a qualitative (dichotomous) variable, and data 313 
on prior antibiotic use in primary care have been collected over relatively short inpatient stay periods or 314 
within a short time frame of between 1 and 6 months, prior to the MRGN detection in hospital [8, 29].   315 
The multivariate regression models in phase 1 (matched controls) indicated that previous exposure to the 316 
cephalosporin antibiotic group (second and third generation) and the fluoroquinolone antibiotic group 317 
(during the previous 12 month period as outpatients) were independent predictors for the detection of 318 
MRGN bacteria in hospital.  In 2011, a population based study (i.e. ecological in design) was conducted 319 
to assess the relationship between antibiotic prescribing in the community and the incidence of hospital 320 
detected MRGN in the present study site (AAH).  The analysis of data in the latter ecologic-level research 321 
demonstrated a significant positive association (with a lag of 4 months) between the prescribing of 322 
amoxicillin-clavulanic acid, in primary care, and the incidence of hospital detected MRGN [18].  In a 323 
study performed in Switzerland (published in 2011), which investigated the influence of fluoroquinolone 324 
prescribing on antibiotic-resistant Escherichia coli strains, a temporal association between the incidence 325 
of community fluoroquinolone-resistant Escherichia coli isolates and community ciprofloxacin 326 
consumption was documented.  In addition, variations in the use of certain antibiotic agents were 327 
followed by subsequent variations in cefepime resistance rates in Escherichia coli strains.   The 328 
antibiotics implicated included outpatient ciprofloxacin use (with a lag of 4 months) [30, 31].  These 329 
latter studies were ecological in design and therefore were subject to ecological bias.  In the ecological 330 
studies, it was not possible to adjust for the confounding effect of patient factors identified in our patient 331 
 level study.  These confounding effects may have weakened the results of the latter population based 332 
study, i.e. findings of ecological studies are deemed less valid and less generalizable.  In contrast, patient-333 
level studies yield more biologically plausible outcomes [8, 29-32].  334 
The following non-antibiotic host-related risk factors were determined as independent predictors of 335 
MRGN detection in hospital: the presence of genitourinary underlying disease (as a primary diagnosis), 336 
being female, being elderly and having an extended in-hospital stay.  When a host’s immune system is 337 
suppressed, accompanied by the occurrence of neutropenia due, for example, to the administration of 338 
chemotherapy, being elderly, being a neonate or having immune deficiency syndrome, the vulnerability 339 
of the host to acquire resistant bacterial strains is enhanced [10, 33-35].  In the present study, female 340 
patients were shown to be significantly more likely to be in the case group than in the randomly 341 
selected control group.  The pathophysiology of urinary tract infections within female patients may 342 
potentially explain this finding [35-37].  Nonetheless, in the present study being female was significant 343 
in itself, independent of having a urinary tract disorder as the primary diagnosis.  In the present study, 344 
there was a firm linkage between having an extended hospitalisation period and the recovery rate of 345 
MRGN in hospital.  Several previous studies have also reported this latter relationship [8, 10].  The 346 
methodology used was unable to differentiate whether the longer stay was due to the MRGN isolation 347 
or whether the MRGN detection was directly linked to length of stay. 348 
Strengths and limitations of study 349 
This study has several strengths.  Firstly, a large overall sample size of patients was examined. Most 350 
previously published studies have been more limited in scope.  Secondly, the data used were primarily 351 
recorded for another purpose, i.e. data were recorded as part of routine practice, which, in turn, 352 
minimised information bias.  Thirdly, this study was performed in two stages. This latter technique 353 
allowed the identification of further patient-related predictors for the isolation of MRGN organisms.  354 
Fourthly, the data utilised in the present investigation was gathered at the individual patient level.  The 355 
majority of previous studies had ecologic designs.  Notably, this study is unique in this area of research 356 
due to following: (i) this was the first patient-level study in the United Kingdom that connected 357 
previous antibiotic prescribing in outpatients with MRGN identification in hospital and (ii) the data 358 
 regarding antibiotic prescription were collected from highly reliable databases, i.e. National Health 359 
Services databases and surveillance systems.  360 
Despite these strengths, the study had a number of limitations.   No adjustment was possible for any 361 
variation of infection control practices that were in the place in the study site hospital during the study 362 
period.  The performance indicator reports generated by the infection control team within AAH, 363 
however, showed that the monthly compliance rate to hand hygiene and environmental 364 
decontamination among the hospital staff was approximately 99.0% and 93% respectively across the 365 
study period.  These data present confidence that cross-contamination rates were likely to be low in the 366 
study site hospital over the study period, i.e. the rate of MRGN transmission (from patient to patient) 367 
was low.  It was not possible to control for exposure to antibiotics during the hospital stay.  Accounting 368 
for travel or overseas infection acquisition was also not possible.  There was no possibility to report the 369 
patients who were identified as carriers of an MRGN during a previous hospital stay.  It was not 370 
possible to count and compare the number of clinical samples taken from control groups against case 371 
patient group (i.e., as there was no MRGN screening policy in NHSCT), some controls might be false 372 
negative.  These latter factors may partially explain the percentage of variance that was unaccounted 373 
for in the logistic regression modelling.  Furthermore, in the present study, the antibiotic dispensing in 374 
primary care was used as a surrogate of antibiotic exposure in individual patients.  This may have 375 
resulted in an overestimation of antibiotic use as non-adherence to full courses of antibiotics is well 376 
documented.  377 
Conclusion  378 
The study identified the independent association between previous exposure (in primary care) to certain 379 
antibiotic groups (second and third generation cephalosporins and fluoroquinolones) and the prevalence 380 
rate of MRGN bacteria detected in secondary care.  The results of this study also demonstrated that the 381 
following ‘non-antibiotic’ factors are independently associated with the detection of MRGN bacteria in 382 
hospital: prolonged hospitalisation, being female, presence of genitourinary disease (as a primary 383 
diagnosis) and older age.  The study also benchmarked the prevalence rate of MRGN pathogens in a 384 
UK medium sized hospital over the study period.  It is possible that a significant proportion of patients 385 
 may have been prescribed antibiotics (according to the reasons listed) inadvertently. To reduce the 386 
selection of MRGNs, adherence to “antibiotic stewardship” and/or antibiotic guidelines is essential.    387 
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[reference: 002/14].  For this type of study (retrospective in design), formal individual patient consent 405 
was not required. 406 
 407 
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 543 
 Table 1 Microbiological characteristics of the MRGN isolates recovered from the case patients 544 
in Antrim Area Hospital (January 2012 to December 2013).  545 
Characteristics Number (%) 
Isolate type (n = 98)  
 E. coli 73 (75.3) 
 K. pneumoniae 8 (8.2) 
 K. oxytoca 1 (1.0) 
 Coliformsa 8 (8.2) 
 P. mirabilis 3 (3.1) 
 M. morganii 2 (2.1) 
 E. aerogenes 1 (1.0) 
 E. cloacae 1 (1.0) 
 Unknown/undetermined                            1 (1.0) 
Isolate culture site (n = 98)  
 Urine 65 (66.3) 
 Blood  9 (9.2) 
 Wound 7 (7.1) 
 Sputum 4 (4.1) 
 Other 13 (13.3) 
Isolate origin/source (n = 98)  
 Hospital-onsetb 44 (44.9) 
 Community-onsetc 54 (55.1) 
Time to MRGN detectiond  
Mean, days (CI 95%) 
6.0 (4.2-7.8) 
 546 
aRefers to unidentified gram-negative rod bacterial isolates, i.e. these isolates were tested for 547 
ESBL production 548 
bClassified when MRGN stain recovered 48 hours or more after hospital admission 549 
c Classified when MRGN isolate recovered < 48 hours after hospital admission  550 
dTime from hospital admission to MRGN isolation. 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 Table 2 Clinical and general characteristics of the case patients and those of matched (phase 1) 563 
and randomly selected control patients (phase 2), Antrim Area Hospital, January 2012-564 
December 2013  565 
Characteristics Case 
patients  
(n = 98) 
Matched 
control 
patients 
 (n = 196) 
P 
value 
Randomly 
selected 
control 
patients 
(n = 200) 
P value 
Age, mean (SD), years 73.3 (15.4) 72.2 (16.7) <0.155 61.1 (20.9) <0.001 
Age category, n (%)          
<0.309 
      
<0.001 
 16-65 23 (23.5) 49 (25.0)  96 (48.0)  
 >65 75 (76.5) 147 (75.0)  104 (52.0)  
Age-adjusted Charlson 
co-morbidity index score, 
mean (SD) 
3.8 (1.9) 3.7 (1.5) <0.712 2.9 (2.0) <0.001 
Gender, n (%)   1.000         
0.065 
 Male 35 (35.7) 70 (35.7)  94 (47.0)  
 Female 63 (64.3) 126 (64.3)  106 (53.0)  
Length of in-hospital stay, 
mean (SD), days                    13.6 (16.3) 
 
7.6 (9.1) 
 
<0.001 
 
5.0 (11.1) <0.001 
Admission ward, n (%)   1.000  0.001 
 A&E 19 (19.4) 38 (19.4)  52 (26.0)  
 B1 31 (31.6) 62 (31.6)  27 (13.5)  
 B2 16 (16.3) 32 (16.3)  26 (13.0)  
 C5 5 (5.1) 10 (5.1)  17 (8.5)  
 C6 10 (10.2) 20 (10.2)  12 (6.0)  
 Other 17 (17.3) 34 (17.3)  66 (33.0)  
Medical specialty, n (%)   <0.001  <0.001 
 Medicine 
assessment unit 
12 (12.2) 24 (12.2)  19 (9.5)  
 Care of older 
people 
4 (4.1) 12 (6.1)  10 (5.0)  
 General medicine 41 (41.8) 80 (40.8)  53 (26.5)  
 General surgery 15 (15.3) 33 (16.8)  30 (15.0)  
 Thoracic medicine 6 (6.1) 7 (3.6)  7 (3.5)  
 A&E 1 (1.0) 4 (2.0)  31 (15.5)  
 Cardiology 3 (3.1) 3 (1.5)  23 (11.5)  
 Other 16 (16.3) 33 (16.8)  27 (13.5)  
 566 
 567 
 568 
 569 
 570 
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 572 
 573 
 574 
 575 
 576 
 577 
 578 
 579 
Characteristics Case 
patients  
(n = 98) 
Matched 
control 
patients 
 (n = 196) 
P 
value 
Randomly 
selected 
control 
patients 
(n = 200) 
P value 
Primary underlying 
diseasea, n (%) 
  <0.001  0.001 
 Circulatory system 9 (9.2) 22 (11.2)  31 (15.5)  
 Respiratory system 22 (22.4) 48 (24.5)  25 (12.5)  
 Digestive system 12 (12.2) 35 (17.9)  25 (12.5)  
 Genitourinary system 22 (22.4) 12 (6.1)  16 (8.0)  
 Injury, poisoning 7 (7.1) 19 (9.7)  25 (12.5)  
 Other 26 (26.5) 60 (30.6)  78 (39.0)  
Secondary underlying 
diseasea, n (%) 
  <0.001  0.007 
 Circulatory system 12 (12.2) 31 (15.8)  36 (18.0)  
 Respiratory system 6 (6.1) 20 (10.2)  12 (6.0)  
 Digestive system 5 (5.1) 20 (10.2)  6 (3.0)  
 Genitourinary system 16 (16.3) 13 (6.6)  8 (4.0)  
 External causes of 
morbidity/mortality 
9 (9.2) 22 (11.2)  29 (14.5)  
 Endocrine,  
nutritional disorders 
7 (7.1) 9 (4.6)  10 (5.0)  
 Other 43 (43.8) 81 (41.3)  99 (49.5)  
Cephalosporin coursesb,  
mean (SD); total number 
     
 Preceding 3 month 
period 
0.02 
(0.20); 2.0 
0.00 (0.00); 
0.0 
<0.001 0.00 (0.00); 
0.0  
0.154 
 Preceding 6 month 
period 
0.04 
(0.28); 4.0 
0.01 (0.14); 
2.0 
<0.001 0.00 (0.00); 
0.0  
0.044 
 Preceding 12 month 
period 
1.82 
(4.28); 
178.0 
0.45 (1.81); 
88.0  
0.039 0.46 (2.14); 
92.0  
<0.001 
 Table 2 Continued 580 
Characteristics Case 
patients 
(n = 98) 
Control 
patients 
 (n = 196) 
P value Randomly 
selected 
control 
patients 
(n = 200) 
p 
value 
Penicillin combination 
courses,b  mean (SD); 
total number 
     
 Preceding 3 
month period 
0.16 (0.47); 
16.0 
0.1 (0.42); 
20.0  
<0.001 0.11 (0.54); 
22.0  
0.069 
 Preceding 6 
month period   
0.24 (0.59); 
24.0 
0.15 (0.51); 
29.0 
<0.001 0.18 (0.74); 
36.0 
0.041 
 Preceding 12 
month period  
0.47 (0.88); 
46.0 
0.27 (0.77); 
53.0 
0.589 0.30 (1.21); 
60.0 
0.001 
Macrolide coursesb,  
mean (SD); total 
number 
     
 Preceding 3 
month period  
0.13 (0.34); 
13.0 
0.11 (0.47); 
22.0 
<0.001 0.13 (0.38); 
26.0 
0.614 
 Preceding 6 
month period  
0.26 (0.56); 
26.0 
0.18 (0.65); 
35.0 
<0.001 0.19 (0.60); 
38.0 
0.089 
 Preceding 12 
month period  
0.37 (0.74); 
36.0 
0.32 (0.95); 
63.0 
0.239 0.31 (0.93); 
62.0 
0.067 
Fluoroquinolone 
coursesb,  mean (SD); 
total number 
     
 Preceding 3 
month period   
0.14 (0.50); 
14.0 
0.05 (0.27); 
10.0 
<0.001 0.05 (0.26); 
10.0 
0.018 
 Preceding 6 
month period 
0.24 (0.76); 
24.0 
0.07 (0.31); 
14.0 
<0.001 0.07 (0.33); 
14.0  
0.005 
 Preceding 12 
month period  
0.43 (1.27); 
42.0 
0.11 (0.40); 
22.0 
<0.001 0.15 (0.69); 
30.0 
0.011 
 581 
B1 medical admissions, B2 general medicine, C5 female surgery, C6 male surgery. 582 
aClassified according to the international classification of diseases. 583 
bNumbers representing the count of the treatment courses within primary care.  584 
Variables with p values ≤0.25 are displayed in bold; these P values refer to comparison of cases 585 
with controls in both study phases.   586 
 587 
 588 
 589 
 Table 3 Output of multivariate analyses (carried out in phase 1 and phase 2), regarding 590 
variables that were independently associated with MRGN bacteria. 591 
Model           Variable   B   SE OR   CI 95%  P value 
1a Hospitalisation period 0.040 0.011 1.04 1.02-1.06 <0.001 
Primary diagnosis       
 Circulatory system   1   
 Digestive system -0.160 0.535 0.85 0.30-2.43 0.765 
 Genitourinary 
system 
1.489 0.549 4.43 1.51-13.00 0.007 
 Injury, poisoning -0.152 0.624 0.86 0.25-2.92 0.808 
 Respiratory system 0.038 0.492 1.04 0.40-2.72 0.983 
 Other 0.162 0.476 1.18 0.46-2.99 0.733 
1b Hospitalisation period 0.041 0.011 1.04 1.02-1.07 <0.001 
1c 
 
Hospitalisation period 0.040 0.011 1.04 1.02-1.06 <0.001 
Second and third 
generation cephalosporins 
0.177 0.061 1.19 1.06-1.35 0.004 
Fluoroquinolones 0.438 0.193 1.55 1.06-2.26 0.023 
 592 
B coefficient, SE standard error, OR odds ratio.  593 
Variables with P values ≤0.05 are displayed in bold. 594 
a, b, c Evaluated antibiotic courses over periods of   a3 months, b6 months and c12 months within 595 
primary care prior to hospitalisation. 596 
 597 
 598 
 599 
 600 
 601 
 602 
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 604 
 605 
 606 
 607 
 608 
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 Table 3 Continued 610 
 611 
B coefficient, SE standard error, OR odds ratio.  612 
Variables with P values ≤0.05 are displayed in bold. 613 
a, b, c Evaluated antibiotic courses over periods of   a3 months, b6 months and c12 months within 614 
primary care prior to hospitalisation. 615 
 616 
 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
Model         Variable B   SE OR   CI  95%  P 
value 
2a,b,c Hospitalisation period 0.053 0.014 1.06 1.03-1.09 <0.001 
Primary diagnosis      
 Circulatory system   1   
 Digestive system 0.928 0.566 2.53 0.84-7.67 0.101 
 Genitourinary system 2.022 0.556 7.56 2.54-22.45 <0.001 
 Injury, poisoning 0.393 0.635 1.48 0.43-5.14 0.537 
 Respiratory system 0.976 0.530 2.65 0.94-7.50 0.066 
 Other 0.828 0.488 2.29 0.88-5.96 0.090 
Age 0.037 0.009 1.04 1.02-1.06 <0.001 
Gender      
 Male   1   
 Female 0.813 0.300 2.26 1.25- 4.06 0.007 
  630 
 631 
Fig. 1 Average number of antibiotic treatment courses (of second and third generation cephalosporins, 632 
fluoroquinolones, penicillin combinations and macrolides), which were prescribed for the cases, matched 633 
(phase 1) and randomly selected control patients (phase 2) in primary care, during the previous 3 month, 634 
6 month and 12 month periods. 635 
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